Arterial pH and N-balances in APD

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
rajnish mehrotra, md, Harborview Injury Prevention and Research Center
ClinicalTrials.gov Identifier:
NCT00586131
First received: December 21, 2007
Last updated: September 29, 2014
Last verified: September 2014
  Purpose

This study will test the hypothesis that by slightly lowering the acidity of blood (or increasing the pH), dialysis patients utilize protein and amino acids more efficiently.


Condition Intervention Phase
End-stage Renal Disease
Other: ammonium chloride or sodium citrate/citric acid
Other: Ammonium chloride or sodium citrate/citric acid
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Effect of Arterial pH on N-balances of Patients Undergoing Automated Peritoneal Dialysis

Resource links provided by NLM:


Further study details as provided by Los Angeles Biomedical Research Institute:

Primary Outcome Measures:
  • N-balances [ Time Frame: 20 days ] [ Designated as safety issue: No ]

Enrollment: 8
Study Start Date: September 2003
Study Completion Date: April 2008
Primary Completion Date: April 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
Low Normal pH (between 7.36 and 7.38)
Other: ammonium chloride or sodium citrate/citric acid
Dose dictated by changes in pH
Active Comparator: 2
High Normal pH (7.44-7.46)
Other: Ammonium chloride or sodium citrate/citric acid
dictated by pH

Detailed Description:

The normal range of pH of the blood (measure of acid-base balance of body) is rather large. It is defined as a range of pH between 7.38 and 7.44. There is evidence to suggest that a high normal arterial pH (7.43-7.45) preserves nutritional status of individuals better than a low normal arterial pH (7.36-7.38). We will test this hypothesis in a small group of stable patients with end-stage renal disease undergoing automated peritoneal dialysis. It needs to be noted that all pH levels to be attained in this study are considered to be normal. The primary outcome measure for the study will be the N-balance. The changes in blood pH will be obtained by medications (ammonium chloride for lower pH and sodium bicarbonate for higher pH).

Study Procedures: A total of eight subjects with end-stage renal disease undergoing automated peritoneal dialysis will be recruited. The initial study procedures will be for purposes of screening individuals for the study. The subjects will perform 24-hour collection of urine and dialysate to assess dialysis dose and a peritoneal equilibration test to evaluate the transport properties of the peritoneum. Only those subjects who receive the minimum dialysis dose and have an average peritoneal transport type will enter the study. During this phase, the subjects will maintain a food diary to evaluate dietary preferences and dietary calorie and protein intake. These data will be used to prepare the diets for the subjects when they are admitted to the GCRC. The next two weeks will be used to evaluate the response of arterial pH to the use of the low alkali solution. If, at the end of two weeks, the arterial pH is not in the desired range, the subjects will require ammonium chloride supplementation to achieve the lower pH. In such subjects, ammonium chloride supplementation will be used for all phases of the study.

Qualifying subjects will be hospitalized in the GCRC for 41 days. The entire period of hospitalization will be divided into two equal phases of 20.5 days each: one will be the low pH phase (low alkali dialysis solution with/without ammonium chloride) and the second will be the high pH phase (high alkali dialysis solution with sodium bicarbonate with/without ammonium chloride). Nitrogen balance will be estimated during the entire period of hospitalization. N-intake is a sum of dietary and medicinal intake, while N-output will be N-losses in dialysate, urine and feces. The N-balance will be the difference between N-intake and N-output. The second outcome measure will be leucine turnover studies. Leucine turnover studies will be performed on days 21 and 41. Leucine turnover studies provide information regarding rates of total body protein synthesis and total body protein degradation as well as rates of leucine oxidation. The study will take 10 hours each - the initial 4 hours will be after an overnight fast and the last six hours will be while being fed. The third outcome measure will be the content of some proteins in a sample of muscle biopsy. Muscle biopsy will be performed on days 21 and 41 after the completion of leucine turnover studies. Finally, nutritional assessment will be performed at the time of patient admission, on day 21 and 41. On days 21 and 41, the nutritional assessment will be performed prior to the start of the leucine turnover studies.

The subjects will be compensated for participation in this study -the amount of compensation will be dependent upon the degree of participation of subjects.

Risk-benefit Assessment: The risks of the study include the risks of performing a muscle biopsy, discomfort associated with the placement of the feeding tube, emotional problems associated with prolonged hospitalization in the GCRC and risks associated with venipuncture. There are no direct benefits to the subjects as a result of their participation in this study. However, if we demonstrate that the higher arterial pH is better at preservation of nutritional status, it may have the potential of decreasing the prevalence and/or severity of protein-energy malnutrition in patients undergoing automated peritoneal dialysis.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Men and women from any ethnic/racial group < 65 years.
  2. Treatment with CPD for 6 months and current treatment with APD for at least one month.
  3. Hemoglobin of at least 11.0 g/dl.
  4. Stable dose of erythropoietin treatment for at least the preceding three months.
  5. Subjects with normal nutritional status to mild malnutrition:

    1. Serum albumin > 3.3 g/dl
    2. Relative body weight of 90-120% of the NHANES II median body weight for a given height, age range, gender and frame size.
    3. A normalized protein equivalent of total nitrogen appearance (nPNA) > 0.80 g/kg actual body weight/day at the time of screening.
  6. D/P Cr between 0.48 and 0.81 on the PET performed at the time of the screen.
  7. Total (renal + peritoneal) weekly Kt/V urea > 1.70 and creatinine clearance > 50 L/wk/1.73 m2.
  8. No evidence of primary or secondary (viz., ischemic, neuropathic) myopathy

Exclusion Criteria:

  1. History of active cancer other than basal cell carcinoma.
  2. Symptomatic severe ischemic heart disease, uncontrolled severe dysrhythmias, uncontrolled congestive heart failure, poorly controlled hypertension, severe musculoskeletal disease, arthritis or amputation of the lower extremities.
  3. Insulin requiring diabetes mellitus.
  4. Patients who received L-carnitine or anabolic hormones (other than erythropoietin) within the previous 6 months.
  5. Use of CaCO3 as phosphate binder.
  6. Severe lung or liver disease, uncontrolled asthma, active vasculitis.
  7. Severe chronic infection or any other acute or chronic inflammatory or catabolic illnesses (e.g., active tuberculosis, AIDS, osteomyelitis).
  8. Psychosis, inability to give informed consent, evidence that patient will not comply with study protocol.
  9. Alcohol or other recreational drug abuse.
  10. Pregnancy (rare in CPD patients).
  11. Patients who are physically and/or psychologically incapable of undergoing the protocol.

    -

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00586131

Locations
United States, California
Los Angeles Biomedical Research Institute
Torrance, California, United States, 90502
Sponsors and Collaborators
Los Angeles Biomedical Research Institute
Investigators
Principal Investigator: Rajnish Mehrotra, MD Los Angeles Biomedical Research Institute
  More Information

No publications provided by Los Angeles Biomedical Research Institute

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: rajnish mehrotra, md, Chief, Harborview Injury Prevention and Research Center
ClinicalTrials.gov Identifier: NCT00586131     History of Changes
Other Study ID Numbers: 11043
Study First Received: December 21, 2007
Last Updated: September 29, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by Los Angeles Biomedical Research Institute:
end-stage renal disease
automated peritoneal dialysis
metabolic acidosis
nitrogen balances

Additional relevant MeSH terms:
Kidney Diseases
Kidney Failure, Chronic
Renal Insufficiency
Renal Insufficiency, Chronic
Urologic Diseases
Citric Acid
Anticoagulants
Chelating Agents
Hematologic Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Sequestering Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on October 22, 2014